CORRECTION Open Access

Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

(2019) 21:114



Kosuke Ebina^{1*}, Motomu Hashimoto², Wataru Yamamoto^{2,3}, Toru Hirano⁴, Ryota Hara⁵, Masaki Katayama⁶, Akira Onishi⁷, Koji Nagai⁸, Yonsu Son⁹, Hideki Amuro⁹, Keiichi Yamamoto¹⁰, Yuichi Maeda⁴, Koichi Murata², Sadao Jinno⁷, Tohru Takeuchi⁸, Makoto Hirao¹, Atsushi Kumanoqoh⁴ and Hideki Yoshikawa¹

Correction to: Arthritis Res Ther https://doi.org/10.1186/s13075-019-1880-4

Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process. The original article [1] has been corrected.

In Fig. 1b, the heading should read: Adjusted survival due to lack of effectiveness

In Fig. 2b, the heading should read: Adjusted survival due to toxic adverse events

In addition, the authors would like to update the legends of Figure 1, 2, 3 and 4 to the following:

Fig. 1 Drug survival rates due to lack of effectiveness in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 2 Drug survival rates due to toxic adverse events in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN =

etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 3 Drug survival rates due to remission in a non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 4 Overall drug survival rates (excluding non-toxic reasons and remission) in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

The publishers apologise for the errors. The corrected figures are given below:

Full list of author information is available at the end of the article



^{*} Correspondence: k-ebina@umin.ac.jp

¹Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan

Author details

¹Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan. ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan. ⁴Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan. ⁵The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan. ⁶Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan. ⁷Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan. ⁸Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan. ⁹First Department of Internal Medicine, Kansai Medical University, Osaka, Japan. ¹⁰Department of Medical Informatics, Wakayama Medical University Hospital, Wakayama, Japan.

Received: 15 April 2019 Accepted: 15 April 2019 Published online: 06 May 2019

Reference

 Ebina, et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. Arthritis Res Ther. 2019;21:91 https://doi.org/10.1186/s13075-019-1880-4.




Fig. 1 Drug survival rates due to lack of effectiveness in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs




Fig. 2 Drug survival rates due to toxic adverse events in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs